|
1
|
Yamashita J and McCauley LK:
Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent
Pract. 12 3 Suppl:S233–S247. 2012. View Article : Google Scholar
|
|
2
|
Ruggiero SL, Dodson TB, Fantasia J,
Goodday R, Aghaloo T, Mehrotra B and O'Ryan F: American Association
of Oral and Maxillofacial Surgeons: American Association of Oral
and Maxillofacial Surgeons position paper on medication-related
osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg.
72:1938–1956. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lipton A, Steger GG, Figueroa J, Alvarado
C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin
KS, et al: Randomized active-controlled phase II study of denosumab
efficacy and safety in patients with breast cancer-related bone
metastases. J Clin Oncol. 25:4431–4437. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fizazi K, Lipton A, Mariette X, Body JJ,
Rahim Y, Gralow JR, Gao G, Wu L, Sohn W and Jun S: Randomized phase
II trial of denosumab in patients with bone metastases from
prostate cancer, breast cancer, or other neoplasms after
intravenous bisphosphonates. J Clin Oncol. 27:1564–1571. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Smith MR, Egerdie B, Hernández Toriz N,
Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic
A, et al: Denosumab in men receiving androgen-deprivation therapy
for prostate cancer. N Engl J Med. 361:745–755. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stopeck AT, Lipton A, Body JJ, Steger GG,
Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA,
Viniegra M, et al: Denosumab compared with zoledronic acid for the
treatment of bone metastases in patients with advanced breast
cancer: A randomized, double-blind study. J Clin Oncol.
28:5132–5139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Henry DH, Costa L, Goldwasser F, Hirsh V,
Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A,
Vadhan-Raj S, et al: Randomized, double-blind study of denosumab
versus zoledronic acid in the treatment of bone metastases in
patients with advanced cancer (excluding breast and prostate
cancer) or multiple myeloma. J Clin Oncol. 29:1125–1132. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fizazi K, Carducci M, Smith M, Damião R,
Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, et al:
Denosumab versus zoledronic acid for treatment of bone metastases
in men with castration-resistant prostate cancer: A randomised,
double-blind study. Lancet. 377:813–822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Smith MR, Saad F, Coleman R, Shore N,
Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, et al:
Denosumab and bone-metastasis-free survival in men with
castration-resistant prostate cancer: Results of a phase 3,
randomised, placebo-controlled trial. Lancet. 379:39–46. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Scagliotti GV, Hirsh V, Siena S, Henry DH,
Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M,
Mehta ND, et al: Overall survival improvement in patients with lung
cancer and bone metastases treated with denosumab versus zoledronic
acid: Subgroup analysis from a randomized phase 3 study. J Thorac
Oncol. 7:1823–1829. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taylor KH, Middlefell LS and Mizen KD:
Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J
Oral Maxillofac Surg. 48:221–223. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Diz P, López-Cedrún JL, Arenaz J and
Scully C: Denosumab-related osteonecrosis of the jaw. J Am Dent
Assoc. 143:981–984. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Malan J, Ettinger K, Naumann E and Beirne
OR: The relationship of denosumab pharmacology and osteonecrosis of
the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 114:671–676.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pichardo SE, Kuypers SC and van Merkesteyn
JP: Denosumab osteonecrosis of the mandible: A new entity? A case
report. J Craniomaxillofac Surg. 41:e65–e69. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Olate S, Uribe F, Martinez F, Almeida A
and Unibazo A: Osteonecrosis of the jaw in patient with denosumab
therapy. Int J Clin Exp Med. 7:3707–3709. 2014.PubMed/NCBI
|
|
16
|
O'Halloran M, Boyd NM and Smith A:
Denosumab and osteonecrosis of the jaws-the pharmacology,
pathogenesis and a report of two cases. Aust Dent J. 59:516–519.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ohga N, Yamazaki Y, Tsuboi K and Kitagawa
Y: Healing of osteonecrosis of the jaw (ONJ) after discontinuation
of denosumab in a patient with bone metastases of colorectal
cancer: A case report and hypothesis. Quintessence Int. 46:621–626.
2015.PubMed/NCBI
|
|
18
|
You Tm, Lee KH, Lee SH and Park W:
Denosumab-related osteonecrosis of the jaw: A case report and
management based on pharmacokinetics. Oral Surg Oral Med Oral
Pathol Oral Radiol. 120:548–553. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Matsushita Y, Hayashida S, Morishita K,
Sakamoto H, Naruse T, Sakamoto Y, Yamada SI, Yanamoto S, Fujita S,
Ikeda T and Umeda M: Denosumab-associated osteonecrosis of the jaw
affects osteoclast formation and differentiation: Pathological
features of two cases. Mol Clin Oncol. 4:191–194. 2016.PubMed/NCBI
|
|
20
|
Yamagata K, Nagai H, Baba O, Uchida F,
Kanno N, Hasegawa S, Yanagawa T and Bukawa H: A case of brain
abscess caused by medication-related osteonecrosis of the jaw. Case
Rep Dent. 2016:70386182016.PubMed/NCBI
|
|
21
|
Owosho AA, Blanchard A, Levi L, Kadempour
A, Rosenberg H, Yom SK, Farooki A, Fornier M, Huryn JM and Estilo
CL: Osteonecrosis of the jaw in patients treated with denosumab for
metastatic tumors to the bone: A series of thirteen patients. J
Craniomaxillofac Surg. 44:265–270. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Advisory Task Force on
Bisphosphonate-Related Ostenonecrosis of the Jaws, American
Association of Oral and Maxillofacial Surgeons: American
Association of Oral and Maxillofacial Surgeons position paper on
bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac
Surg. 65:369–376. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ruggiero SL, Dodson TB, Assael LA,
Landesberg R, Marx RE and Mehrotra B: American Association of Oral
and Maxillofacial Surgeons: American Association of Oral and
Maxillofacial Surgeons position paper on bisphosphonate-related
osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg. 67 5
Suppl:S2–S12. 2009. View Article : Google Scholar
|
|
24
|
Marx RE: Pamidronate (Aredia) and
zoledronate (Zometa) induced avascular necrosis of the jaws: A
growing epidemic. J Oral Maxillofac Surg. 61:1115–1117. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cummings SR, San Martin J, McClung MR,
Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A,
et al: Denosumab for prevention of fractures in postmenopausal
women with osteoporosis. N Engl J Med. 361:756–765. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Roux C, Hofbauer LC, Ho PR, Wark JD,
Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola
S, Papaioannou N, et al: Denosumab compared with risedronate in
postmenopausal women suboptimally adherent to alendronate therapy:
Efficacy and safety results from a randomized open-label study.
Bone. 58:48–54. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakamura T, Matsumoto T, Sugimoto T, Hosoi
T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, et al:
Clinical trials express: Fracture risk reduction with denosumab in
Japanese postmenopausal women and men with osteoporosis: Denosumab
fracture intervention randomized placebo controlled trial (DIRECT).
J Clin Endocrinol Metab. 99:2599–2607. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dinca O, Bucur MB, Bodnar D, Vladan C and
Bucur A: Extensive osteonecrosis of the mandible after therapy with
denosumab following bisphosphoantes therapy. Acta Endo. 10:457–462.
2014. View Article : Google Scholar
|
|
29
|
Capozzi A, Lello S and Pontecorvi A: The
inhibition of RANK-ligand in the management of postmenopausal
osteoporosis and related fractures: The role of denosumab. Gynecol
Endocrinol. 30:403–408. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Baron R, Ferrari S and Russell RG:
Denosumab and bisphosphonates: Different mechanisms of action and
effects. Bone. 48:677–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qi WX, Tang LN, He AN, Yao Y and Shen Z:
Risk of osteonecrosis of the jaw in cancer patients receiving
denosumab: A meta-analysis of seven randomized controlled trials.
Int J Clin Oncol. 19:403–410. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fedele S, Porter SR, D'Aiuto F, Aljohani
S, Vescovi P, Manfredi M, Arduino PG, Broccoletti R, Musciotto A,
Di Fede O, et al: Nonexposed variant of bisphosphonate-associated
osteonecrosis of the jaw: A case series. Am J Med. 123:1060–1064.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Campisi G, Fedele S, Fusco V, Pizzo G, Di
Fede O and Bedogni A: Epidemiology, clinical manifestations, risk
reduction and treatment strategies of jaw osteonecrosis in cancer
patients exposed to antiresorptive agents. Future Oncol.
10:257–275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Patel V, McLeod NM, Rogers SN and Brennan
PA: Bisphosphonate osteonecrosis of the jaw-a literature review of
UK policies versus international policies on bisphosphonates, risk
factors and prevention. Br J Oral Maxillofac Surg. 49:251–257.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Coleman RE: Metastatic bone disease:
Clinical features, pathophysiology and treatment strategies. Cancer
Treat Rev. 27:165–176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Body JJ, Lipton A, Gralow J, Steger GG,
Gao G, Yeh H and Fizazi K: Effects of denosumab in patients with
bone metastases with and without previous bisphosphonate exposure.
J Bone Miner Res. 25:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Otto S, Baumann S, Ehrenfeld M and Pautke
C: Successful surgical management of osteonecrosis of the jaw due
to RANK-ligand inhibitor treatment using fluorescence guided bone
resection. J Craniomaxillofac Surg. 41:694–698. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vyas S, Hameed S and Murugaraj V:
Denosumab-associated osteonecrosis of the jaw-a case report. Dent
Update. 41:449–450. 2014.PubMed/NCBI
|
|
39
|
Uyanne J, Calhoun CC and Le AD:
Antiresorptive drug-related osteonecrosis of the jaw. Dent Clin
North Am. 58:369–384. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Scott LJ and Muir VJ: Denosumab: In the
prevention of skeletal-related events in patients with bone
metastases from solid tumours. Drugs. 71:1059–1069. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Epstein MS, Ephros HD and Epstein JB:
Review of current literature and implications of RANKL inhibitors
for oral health care providers. Oral Surg Oral Med Oral Pathol Oral
Radiol. 116:e437–e442. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Saad F, Brown JE, van Poznak C, Ibrahim T,
Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, et
al: Incidence, risk factors, and outcomes of osteonecrosis of the
jaw: Integrated analysis from three blinded active-controlled phase
III trials in cancer patients with bone metastases. Ann Oncol.
23:1341–1347. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Khan AA, Morrison A, Hanley DA, Felsenberg
D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis
S, et al: Diagnosis and management of osteonecrosis of the jaw: A
systematic review and international consensus. J Bone Miner Res.
30:3–23. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ristow O, Otto S, Troeltzsch M,
Hohlweg-Majert B and Pautke C: Treatment perspectives for
medication-related osteonecrosis of the jaw (MRONJ). J
Craniomaxillofac Surg. 43:290–293. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schipmann S, Metzler P, Rössle M, Zemann
W, von Jackowski J, Obwegeser JA, Grätz KW and Jacobsen C:
Osteopathology associated with bone resorption inhibitors-which
role does Actinomyces play? A presentation of 51 cases with
systematic review of the literature. J Oral Pathol Med. 42:587–593.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Katsarelis H, Shah NP, Dhariwal DK and
Pazianas M: Infection and medication-related osteonecrosis of the
jaw. J Dent Res. 94:534–539. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Miller M and Haddad AJ: Cervicofacial
actinomycosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
85:496–508. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hansen T, Kunkel M, Kirkpatrick CJ and
Weber A: Actinomyces in infected osteoradionecrosis-underestimated?
Hum Pathol. 37:61–67. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bartkowski SB, Zapala J, Heczko P and
Szuta M: Actinomycotic osteomyelitis of the mandible: Review of 15
cases. J Craniomaxillofac Surg. 26:63–67. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Goldberg MH: Diagnosis and treatment of
cervicofacial actinomycosis. Oral Maxillofac Surg Clin North Am.
15:51–58. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kuyama K, Sun Y, Fukui K, Maruyama S,
Ochiai E, Fukumoto M, Ikeda N, Kondoh T, Iwadate K, Takagi R, et
al: Tumor mimicking actinomycosis of the upper lip: Report of two
cases. Oral Med Pathol. 15:95–99. 2011. View Article : Google Scholar
|
